Tranzyme Partners with Bristol-Myers, Lilly Fights Patent Cliff: Healthcare Business Recap

Tranzyme Pharma (NASDAQ:TZYM)  Closing price $0.52

On Friday, Tranzyme reported the successful finalization of its chemistry-based drug discovery partnership with Bristol-Myers Squibb Company (NYSE:BMY). Resulting from their research efforts, the former has transferred compounds to the latter for further development across multiple drug targets. Through the accord, Tranzyme keeps the option to further pursue chosen  collaboration targets for internal development.